Durvalumab plus paclitaxel/carboplatin plus bevacizumab followed by durvalumab, bevacizumab plus olaparib maintenance among patients with newly-diagnosed advanced ovarian cancer without a tumor BRCA1/BRCA2 mutation: Updated results from DUO-O/ENGOT-OV46/GOG-3025 Trial Meeting Abstract
| Authors: | Harter, P.; Wimberger, P.; Okamoto, A.; Reuss, A.; Lim, M. C.; Rubio-Pérez, M. J.; Vardar, M. A.; Scambia, G.; Trédan, O.; Hietanen, S.; Colombo, N.; Chudecka-Glaz, A.; Petru, E.; Lheureux, S.; Van Nieuwenhuysen, E.; Sehouli, J.; Wenham, R.; Ushijima, K.; Indiviglio, S.; Aghajanian, C. |
| Abstract Title: | Durvalumab plus paclitaxel/carboplatin plus bevacizumab followed by durvalumab, bevacizumab plus olaparib maintenance among patients with newly-diagnosed advanced ovarian cancer without a tumor BRCA1/BRCA2 mutation: Updated results from DUO-O/ENGOT-OV46/GOG-3025 Trial |
| Meeting Title: | Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer |
| Journal Title: | Gynecologic Oncology |
| Volume: | 190 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2024 Mar 15-18 |
| Meeting Location: | San Deigo, CA |
| ISSN: | 0090-8258 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2024-11-01 |
| Start Page: | S65 |
| End Page: | S66 |
| Language: | English |
| ACCESSION: | WOS:001330731400087 |
| DOI: | 10.1016/j.ygyno.2024.07.096 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 24 [LBA] -- Source: Wos |
